SCHEMBL14918792

SCHEMBL14918792

Cc1cc(C(=O)/C=C/c2cc(C(C)(C)C)cc(C(C)(C)C)c2)ccc1C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.63
MAPT P10636 2/20 0.63
TP53 P04637 1/20 0.63
CYP3A4 P08684 1/20 0.63
ALOX15 P16050 1/20 0.63
MAPK1 P28482 1/20 0.63
BLM P54132 1/20 0.63
CASP7 P55210 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
HSD17B10 Q99714 1/20 0.63
RXRB P28702 3/20 0.56
NR1H4 Q96RI1 1/20 0.45
NFE2L2 Q16236 1/20 0.45
RXRA P19793 2/20 0.43
RXRG P48443 1/20 0.43
PPARG P37231 1/20 0.43
PPARD Q03181 1/20 0.43
PPARA Q07869 1/20 0.43
TNFRSF1A P19438 1/20 0.43
CYP1B1 Q16678 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14918794 1.00 TDP1 (0.63) TDP1MAPTTP53CYP3A4ALOX15
SCHEMBL14918992 0.84 MAPT (0.81) TDP1MAPTTP53CYP3A4ALOX15
SCHEMBL14918994 0.84 MAPT (0.81) TDP1MAPTTP53CYP3A4ALOX15
SCHEMBL2126269 0.78 SMN1; SMN2 (0.58) TDP1MAPTTP53CYP3A4ALOX15
SCHEMBL2126271 0.78 SMN1; SMN2 (0.58) TDP1MAPTTP53CYP3A4ALOX15
SCHEMBL2307737 0.77 MAPT (1.00) TDP1MAPTTP53CYP3A4ALOX15
SCHEMBL2307743 0.77 MAPT (1.00) TDP1MAPTTP53CYP3A4ALOX15
SCHEMBL4918252 0.77 CYP1B1 (0.67) TDP1MAPTTP53CYP3A4ALOX15
SCHEMBL14918605 0.75 MAPT (0.59) TDP1MAPTTP53CYP3A4ALOX15
SCHEMBL14918608 0.75 MAPT (0.59) TDP1MAPTTP53CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140275049-A1 SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS ELI LILLY AND COMPANY 2014-09-18 US disclosed
WO-2013066640-A1 SUBSTITUTED PYRAZOLE ANALOGUES AS RAR ANTAGONISTS ELI LILLY AND COMPANY (US) 2013-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275049-A1 SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS RARB, RARA, RARG TDP1 3617/4885MAPT 4647/4885TP53 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.